Protocol Ledger

NCT05004350 · Phase II · COMPLETED

A Study Evaluating the Combination of Encorafenib and Cetuximab Versus Irinotecan/Cetuximab or Infusional 5-fluorouracil (5-FU)/Folinic Acid (FA)/Irinotecan (FOLFIRI)/Cetuximab in Chinese Patients With BRAF V600E Mutant

Interventional Phase II clinical trial protocol NCT05004350 sponsored by Pierre Fabre Medicament in Oncology and Hematology, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2021-09-14 Enrollment: 107 participants (ACTUAL) Federal Source: clinicaltrials.gov/study/NCT05004350
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)107 participants (ACTUAL)
Disclosed U.S. Hospital Campuses vs Median (6 sites)4 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT05004350
Protocol FieldVerified Registry Value
NCT IdentifierNCT05004350
Consolidated Lead SponsorPierre Fabre Medicament
Therapeutic Condition CohortOncology and Hematology
Clinical Trial PhasePhase II
Overall Recruitment StatusCOMPLETED
Registered Enrollment107 participants (ACTUAL)
Registered Start Date2021-09-14
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Search related sites and sponsors in the Interactive Directory, explore Oncology and Hematology Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI